display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/adv melanoma (mML)
mML - L2 - BRAF mutant
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab plus SoC KEYNOTE-022

Study type: